Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Rituximab
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide

First Posted Date: 2004-08-25

Last Posted Date: 2017-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 552

Registration Number: NCT00090051

Locations: 🇪🇸
Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain
🇺🇸
Rush-Presbyterian St. Luke'S Medical Center, Chicago, Illinois, United States
🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada

and more 103 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: carboplatin
Drug: cyclophosphamide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-08-24

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 11

Registration Number: NCT00003136

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-24

Last Posted Date: 2013-11-06

Lead Sponsor: Scottish Cancer Therapy Network

Target Recruit Count: 600

Registration Number: NCT00002755

Locations: 🇬🇧
St. James's Hospital, Leeds, England, United Kingdom
🇬🇧
Addenbrooke's NHS Trust, Cambridge, England, United Kingdom
🇬🇧
Cheltenham General Hospital, Cheltenham, England, United Kingdom

and more 17 locations

Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease

Phase 3

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-08-23

Last Posted Date: 2014-01-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005024

Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2004-08-23

Last Posted Date: 2013-12-18

Lead Sponsor: Leiden University Medical Center

Registration Number: NCT00002498

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
🇳🇱
St. Radboud University Hospital, Nijmegen, Netherlands

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-23

Last Posted Date: 2013-05-30

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT00004906

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2004-08-23

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT00002634

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-23

Last Posted Date: 2013-11-06

Lead Sponsor: Scottish Cancer Therapy Network

Target Recruit Count: 2000

Registration Number: NCT00002579

Locations: 🇬🇧
Leicester Royal Infirmary NHS Trust, Leicester, England, United Kingdom
🇬🇧
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
🇬🇧
Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom

and more 7 locations